anifrolumabSLEcorticosteroid
… and consistently after 12 months. These findings suggests that anifrolumab could reduce organ damage accumulation, supporting the potentia…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 199 of 2459rituximabmycophenolate mofetilcyclophosphamideCYCLupus nephritisSLEMMFEnd-Stage Renal Disease (ESRD)Guatemalan Social Security InstituteISLA+3 more
…ntenance in 69% of cases, a total of 14.5% of patients received rituximab as a rescue therapy, while 20.3% were treated with CYC as a rei…
systemic lupus erythematosusSLECF
…Objectives Cognitive symptoms or ‘brain fog’ are common in systemic lupus erythematosus (SLE) and may reflect cognitive fatigue (CF) rather than measur…
Anifrolumabbelimumabrituximabrituximab-treatedsystemic lupus erythematosusSLE
…plained approximately 8% of the variance in δCLASI (R2 = 0.08). Anifrolumab was the only therapy independently associated with significant …
Systemic Lupus ErythematosusprednisoneSLEbelimumabrituximabazathioprinemycophenolatemethotrexateGCRELESSER-PROS registry
…icoids (CG) use is a main driver of organ damage progression in Systemic Lupus Erythematosus (SLE). Updated EULAR SLE recommendations suggest avoiding the c…
BMS-986353Systemic lupus erythematosusSLECD19-directed CAR T cell therapyglucocorticoids
… appropriateness of outcome measures, and lack of control group.BMS-986353 is a CD19-directed CAR T cell therapy, manufactured using the n…
hydroxychloroquinebelimumabrituximabObinutuzumabprednisonelupus nephritismycophenolate mophetilOBZrefractory LNstandard therapy+1 more
…sant; 3/5 rituximab and 4/5 belimumab. Concomitant therapy: 5/5 hydroxychloroquine, 4/5 MMF/Na, 5/5 prednisone (mean baseline dose 15 mg/day (10-1…
99.3%
belimumabSLEGSKstandard therapyGSK
…ower levels of disease activity supports benefits of initiating belimumab treatment earlier in the disease course. Funding: GSK, Original…
LNSLEBelimumabcyclophosphamideGSKmycophenolate mofetilBLISS-LNCYCBELMMF
…72) provide further kidney function maintenance data to support LN treatment decisions.Funding GSK (BEL114054, NCT01639339)Origina…
SLEBafilomycin A13-MAGW4869brefeldin A
…sicular body formation by GW4869 also decreased BAFF secretion. SLE monocytes produced approximately double the levels of BAFF comp…
systemic lupus erythematosusSLEsystemic sclerosisSjDSScSLE-associatedSjögren’s diseasePRECISESADS project
…s Current clinical serology (e.g., ANA, anti-dsDNA, anti-Sm) in systemic lupus erythematosus (SLE) does not fully capture disease heterogeneity. We recently…